Pregabalin prescription patterns in private clinics in Iraq: a cross-sectional study
DOI:
https://doi.org/10.60988/p.v37i2S.220Keywords:
pregabalin; private clinics; neuralgia; neuropathic pain; misuseAbstract
Pregabalin, despite its widespread use across neurology, psychiatry, and primary care, is increasingly recognized for its potential to be misused. Reports have documented rising prescription volumes alongside anecdotal evidence of an expanding illicit market. This study, conducted at private clinics in Diyala, Iraq, between January and December 2024, aimed at evaluating the pregabalin prescribing patterns in Iraqi general practice and at assessing whether its use warrants concern. Pharmacologically, pregabalin exhibits GABA-mimetic properties and may exert direct or indirect effects on the dopaminergic reward pathway. Although its addiction liability at therapeutic doses is considered low, the perception among misusers that pregabalin constitutes a legitimate substitute for illicit substances raises public health concerns. Our study has found that 45% of pregabalin users were aged 60–69 years. Prolonged use (>4 weeks) was observed in 75% of cases and was statistically significant (p<0.001). Insomnia accounted for 43% of prescriptions, also reaching statistical significance (p<0.001). These findings underscore the importance of thorough clinical assessment prior to pregabalin initiation, including evaluation of any history of substance misuse and vigilance for signs of abuse during treatment.
References
1. Evoy K.E., Sadrameli S., Contreras J., Covvey J.R., Peckham A.M., Morrison M.D. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs 81(1), 125–156, 2021. DOI: 10.1007/s40265-020-01432-7
2. Bonnet U., Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur. Neuropsychopharmacol. 27(12), 1185–1215, 2017. DOI: 10.1016/j.euroneuro.2017.08.430
3. Servais L., Huberland V., Richelle L. Misuse of pregabalin: a qualitative study from a patient’s perspective. BMC Public Health 23(1), 1339, 2023. DOI: 10.1186/s12889-023-16051-6
4. Zellner N., Eyer F., Zellner T. Alarmierender pregabalin-missbrauch: prävalenz im Münchener Raum, Konsummuster und Komplikationen. Dtsch Med. Wochenschr. 142(19), e140–e147, 2017. DOI: 10.1055/s-0043-104228
5. Zhou L., Bhattacharjee S., Kwoh C.K., Tighe P.J., Malone D.C., Slack M., et al. Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016. J. Clin. Med. 9(1), 83, 2019. DOI: 10.3390/jcm9010083
6. Montastruc F., Loo S.Y., Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993–2017. JAMA 320(20), 2149–2151, 2018. DOI: 10.1001/jama.2018.12358
7. Al-Husseini A., Wazaify M., Van Hout M.C. Pregabalin misuse and abuse in Jordan: a qualitative study of user experiences. Int. J. Ment. Health Addict. 16(3), 642–654, 2018. DOI: 10.1007/s11469-017-9813-4
8. Benassayag Kaduri N., Dressler R., Abu Ahmad W., Rotshild V. Trends in pregabalin use and prescribing patterns in the adult population: a 10-year pharmacoepidemiologic study. CNS Drugs 38(2), 153–162, 2024. DOI: 10.1007/s40263-024-01064-5
9. Novotny M., Bulla J., Hubl D., Fischer S.K.M., Grosshans M., Gutzeit A., et al. Pregabalin use in forensic hospitals and prisons in German speaking countries-a survey study of physicians. Front. Public Health 11, 1309654, 2024. DOI: 10.3389/fpubh.2023.1309654
10. Mikhael E.M., Jebur N.J., Jamal M.Y., Hameed T.A. Perception, experience, and practice of Iraqi community pharmacists towards customers with substance use disorder. SAGE Open Med. 12, 20503121241275472, 2024. DOI: 10.1177/20503121241275472
